Literature DB >> 15793850

Suppressive effect of ursodeoxycholic acid on type IIA phospholipase A2 expression in HepG2 cells.

Tadashi Ikegami1, Yasushi Matsuzaki, Sugano Fukushima, Junichi Shoda, Jean Luc Olivier, Bernard Bouscarel, Naomi Tanaka.   

Abstract

Phospholipase A(2) IIA (PLA(2)IIA), which plays a crucial role in arachidonic acid metabolism and in inflammation, is upregulated under various pathological conditions, including in the gallbladder and gallbladder bile from patients with multiple cholesterol gallstones, in the liver and kidney of rats with cirrhosis, as well as in the colonic tissue of animals treated with a chemical carcinogen. The administration of ursodeoxycholic acid (UDCA) partially attenuated the PLA(2)IIA expression level in these different models. The aim of this study was to investigate the modulatory effect of UDCA on the PLA(2)IIA expression level at the cellular level. The HepG2 cells were selected to investigate the direct inhibitory effect of UDCA on PLA(2)IIA expression level. The proinflammatory cytokines (interleukin-6 and tumor necrosis factor alpha) -induced PLA(2)IIA expression in HepG2 cells was partially inhibited by the presence of UDCA in a dose-dependent fashion. The effect of UDCA on proinflammatory cytokines-induced PLA(2)IIA expression occurred at the transcriptional level. In addition, among the bile acids tested, this inhibitory effect was UDCA-specific. In conclusion, this study supports the possible alteration of arachidonic acid metabolism and PLA(2)IIA expression level, in particular, as the protective action of UDCA in patients with chronic liver disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15793850     DOI: 10.1002/hep.20630

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  7 in total

Review 1.  Primary biliary cirrhosis: From bench to bedside.

Authors:  Elias Kouroumalis; George Notas
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-08-06

2.  Expression of secreted phospholipase A2-Group IIA correlates with prognosis of gastric adenocarcinoma.

Authors:  Chengwei Zhang; Haipeng Yu; Haiyan Xu; Lanlan Yang
Journal:  Oncol Lett       Date:  2015-09-21       Impact factor: 2.967

3.  Nuclear corepressors mediate the repression of phospholipase A2 group IIa gene transcription by thyroid hormone.

Authors:  Pragya Sharma; Shalini Thakran; Xiong Deng; Marshall B Elam; Edwards A Park
Journal:  J Biol Chem       Date:  2013-04-29       Impact factor: 5.157

4.  Roles of ursodeoxycholic acid in the bile biochemistry and metabolomics in patients with choledocholithiasis: a prospective study.

Authors:  Yaping Guan; Fei Xu; Xiaodong Zhang; Xiao Fu; Jing Wang; Sentao Song; Yan Sun; Qiongying Yuan; Feng Zhu
Journal:  Metabolomics       Date:  2022-07-01       Impact factor: 4.747

5.  A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C.

Authors:  Masao Omata; Haruhiko Yoshida; Joji Toyota; Eiichi Tomita; Shuhei Nishiguchi; Norio Hayashi; Shiro Iino; Isao Makino; Kiwamu Okita; Gotaro Toda; Kyuichi Tanikawa; Hiromitsu Kumada
Journal:  Gut       Date:  2007-06-15       Impact factor: 23.059

6.  A dose-up of ursodeoxycholic acid decreases transaminases in hepatitis C patients.

Authors:  Shuichi Sato; Tatsuya Miyake; Hiroshi Tobita; Naoki Oshima; Junichi Ishine; Takuya Hanaoka; Yuji Amano; Yoshikazu Kinoshita
Journal:  World J Gastroenterol       Date:  2009-06-14       Impact factor: 5.742

Review 7.  Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode.

Authors:  Magd A Kotb
Journal:  Int J Mol Sci       Date:  2012-07-17       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.